Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 21 items

Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538

Bogart, Jeffrey , Wang, Xiaofei , Masters, Gregory , Zhu, Han ... - ESMO - Ann Oncol - 2019

Abstract - Secondary - Primary - Respiratory - CALGB-30610

LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration

Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - ESMO - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633

β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled in the NCCTG-N9831 (Alliance) trial

Caparica, Rafael , Ma, Yaohua , De Angelis, Claudia ... - ESMO - Annals of Oncology - 2020

Abstract - Secondary-not-in-original - Primary - Breast - NCCTG-N9831

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary - Primary - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary - Primary - GU - A031203

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

Das, Rahul K , Furchtgott, Leon , Meyerhardt, Jeffrey A. ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoires in HER2-positive breast cancer: a correlative analysis of the CALGB 40601 (Alliance) clinical trial.

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ESMO - Ann Oncol - 2019

Abstract - Secondary - Primary - Breast - CALGB-40601

Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development.

Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - ESMO - Ann. Oncol. - 2008

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N047B

LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by Immunohistochemistry (IHC) in patients with resected Non-Small Cell Lung Cancer (NSCLC).

Graziano, S. , Paris, E. , Ma, X. , Pignon, J. , Hainaut, P. ... - ESMO - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original - Primary - Respiratory - CALGB-9633

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017

Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702

LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012

Abstract - Secondary-not-in-original - Primary - Respiratory - CALGB-9633

A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients

Innocenti, F , Jiang, C , Sibley, A B , Denning, S , Etheridge, A S ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-80303

Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance)

Innocenti, Federico , Rashid, Naim , Mu, Wancen , Ou, Fang-Shu ... - ESMO - Annals of Oncology - 2019

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study

Janne, P. , Shepherd, F. , Domerg, C. , Le Teuff, G. , Kratzke, R. ... - ESMO - Ann. Oncol. - 2012

Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon

Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014

Abstract - Primary - Primary - GI - C80405

PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

Mayer, Erica L. , Gnant, Michael , DeMichele, Angela , Martin, Miguel ... - ESMO - Annals of Oncology - 2020

Abstract - Primary - Primary - Breast - AFT-05

Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary - Primary - Breast - N063D

Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio

Seymour, L. K. , Le Teuff, G. , Tsao, M. , Brambilla, E. ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary-not-in-original - Meta-Analysis - Respiratory - CALGB-150802 , CALGB-9633

LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation in Completely Resected Non-Small Cell Lung Cancer (NSCLC)

Tsao, M. S. , Hainaut, P. , Bourredjem, A. , Janne, P. A. ... - ESMO - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original - Comprehensive - Respiratory - CALGB-9633

CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy

Venook, A. , Niedzwiecki, D. , Lenz, H. , Mahoney, M. , Innocenti, F. ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary - Primary - GI - CALGB-80405